Jan 17, 2025 · In 2023, BARDA began working with Moderna to help develop mRNA vaccine to prepare for potential public health emergencies (PHEs) caused by influenza viruses, such as avian influenza A(H5N1). In addition, Moderna will design and test an H7N9 mRNA pandemic influenza vaccine in a phase 3 clinical study.

3 days ago · Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving positive results in earlier phases.

Jan 21, 2025 · Moderna will also run a phase 3 trial of a vaccine against H7N9, another strain of avian influenza. Beyond that, the HHS is expecting Moderna to design up to four new flu vaccines that can be put ...

Jan 21, 2025 · Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. The company plans to move into phase 3 clinical trials to test the vaccine in a larger group of people after receiving ...

Jan 17, 2025 · Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, alongside other influenza vaccines, health officials announced Friday.

Jan 20, 2025 · Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development...

Jan 18, 2025 · The U.S. Department of Health and Human Services announced it will award $590 million to Moderna to accelerate the development of influenza vaccines, including to protect against bird flu. "Accelerating the development of new vaccines will allow us to stay ahead and ensure that Americans have the tools they need to stay safe," outgoing HHS Secretary Xavier Becerra said in a statement on Friday.

Jan 18, 2025 · Since 2023, Moderna has been working to create a “pandemic influenza vaccine” which would help protect against certain viruses, including the H5N1 bird flu. The new funds build on the $176 ...

Jul 2, 2024 · Moderna will leverage its domestic large-scale commercial mRNA vaccine manufacturing platforms and ongoing development of mRNA-based seasonal flu vaccines. The award comes as officials confirm more H5N1 avian flu in US cattle and poultry.

Jan 21, 2025 · Moderna has been testing mRNA vaccine candidates for pandemic influenza since 2023, when it began a Phase 1/2 study in adults that assessed shots matched to the H5 and H5 avian flu strains. The company is now preparing to advance one …